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Abstract:  Adenovirus (Ad) vectors, in particular those of the serotype 5, are highly 
attractive for a wide range of gene therapy, vaccine and virotherapy applications (as 
discussed in further detail in this issue). Wild type Ad5 virus can replicate in numerous 
tissue types but to use Ad vectors for therapeutic purposes the viral genome requires 
modification. In particular, if the viral genome is modified in such a way that the viral life 
cycle is interfered with, a specific producer cell line is required to provide trans-
complementation to overcome the modification and allow viral production. This can occur 
in two ways; use of a producer cell line that contains specific adenoviral sequences 
incorporated into the cell genome to trans-complement, or use of a producer cell line that 
naturally complements for the modified Ad vector genome. This review concentrates on 
producer cell lines that complement non-replicating adenoviral vectors, starting with the 
historical HEK293 cell line developed in 1977 for first generation Ad vectors. In addition 
the problem of replication-competent adenovirus (RCA) contamination in viral 
preparations from HEK293 cells is addressed leading to the development of alternate cell 
lines. Furthermore novel cell lines for more complex Ad vectors and alternate serotype Ad 
vectors are discussed. 
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1. Producer cells for non-replicating first generation Ad vectors 
Many therapeutic Ad5 vectors are non-replicating (or replication deficient) whereby the genome is 
deleted in the E1 region often in combination with the E3 region to provide space for alternate gene 
expression cassettes (first generation Ad vectors, see Figure 1). The E1 region encodes proteins 
necessary for the expression of the other early and late genes, hence initiating the viral life cycle. 
Therefore when the E1 region is replaced with an expression cassette to produce the gene product that 
is useful in therapy, such as suicide genes, antigens and antibodies, a producer cell line containing 
adenovirus E1 sequences is required to complement for this region. The E3 region, which encodes 
products that counteract host defense mechanisms, however is dispensable and not essential for viral 
replication in vitro, so it is not necessary to trans-complement for E3 [1].  
Figure 1. Genome structures of first and second generation and high capacity adenovirus 
vectors. Promoters are indicated by black triangles, early and late transcription units are 
indicated by thick and thin arrows respectively. The inverted terminal repeats (ITR) are 
indicated by black squares and the packaging signal, Ψ is indicated. Non-adenoviral 
sequences in the high capacity genome are indicated by a thin line, while transgenes in all 
genomes are indicated by diagonal striped boxes. 
aA very large number of different 
systems are in use with specific extra capacity. For second generation vectors deletion of 3 
gene loci and a conservative 103% genome size was used for these estimates.  
 
 
To trans-complement for the lack of E1 the historic cell line has been HEK293 [2,3] (Table 1). The 
human embryonic kidney (HEK) 293 cell line was developed over 30 years ago through an insertion of 
E1A and E1B sequence [2], from nucleotides (nt) 1 to 4344, into chromosome 19 at 19q13.2 [4].  
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Table 1. E1 complementary producer cell lines
a. 
Cell Line  Parental Cells  Ad Sequence  Promoter 
Requirement 
3’ End 
Requirement 
Ref 
HEK293  Human 
embryonic 
kidney (HEK) 
1 to 4344  Not  applicable 
(N/A) 
N/A [2] 
911  Human 
embryonic 
retinoblasts 
(HER) 
79 – 5789  N/A  N/A  [5] 
pTG6559  A549 505-4034  muPGK 
promoter 
Rabbit -
globin gene 
polyA 
[6] 
PER.C6  HER 459-3510 
 
huPGK 
promoter 
Hepatitis B 
virus polyA 
[7] 
GH329  HeLa 
 
511-3924 huPGK 
promoter 
Yes [8] 
N52.E6  Primary 
human 
amniocytes 
505-3522 muPGK 
promoter 
SV40 splice 
acceptor and 
polyA 
[9] 
HeLa-E1  HeLa 542-3526  CMV bGH  polyA  [10] 
UR  HEL 299  459-3510  RSV-LTR  TK polyA  [11] 
VLI-293
b  HEK293  1 to 4344, 
insertion of 
spacer at 3510 
N/A Hepatitis  B 
virus polyA in 
insert 
[12] 
a  These E1 producer cell lines contain contiguous E1A and E1B sequences. Two additional E1 producer 
  cell lines, which have E1A and E1B inserted separately [13,14], are discussed in the body of text as an 
  alternate method to this historical method. 
b  Although this cell line is novel, it still contains the contiguous E1A and E1B sequences with a Hepatitis 
  B virus polyA at the 3’ end terminating E1B transcription. 
 
The disadvantage with the HEK293 cell line is the potential for the generation of replication-
competent adenovirus (RCA) contamination within the viral preparation. This can occur because many 
first-generation Ad vectors are deleted from nt 400 to 3500 and thus still retain significant homology 
with the cellular DNA allowing for a double crossover recombination event to take place [15] Viruses 2010, 2                  
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(Figure 2). While the occurrence of RCA is very low in the first passages of the virus [16], this is 
problematic for large-scale viral production and clinical applications [15-19] due to safety issues in a 
therapeutic product. In 2001, the FDA established that replication-defective adenoviral vector 
preparation contain less than 1 RCA in 3 x 10
10 viral particles (Biological Response Modifiers 
Advisory Committee). Despite this issue HEK293 was and still remains a major host cell line for Ad 
vector development including development of master cell banks and development and optimization of 
Ad-manufacturing processes [20]. 
Figure 2. RCA generation in HEK293 cells. The complementary regions of Ad5 sequence 
in the vector and the HEK293 genome are aligned at the top of the figure. These regions 
allow for homologous recombination to occur and for the rescue of recombinant competent 
adenovirus. 
 
 
In the 90s, alternate E1 producer cell lines were being evolved (Table 1). One of the first was the 
911 cell line generated by incorporation of Ad5 nt 79 – 5789 into the genome of human embryonic 
retinoblasts (HER) cells [5] through plasmid transfection. The 911 cell line was determined to 
outperform HEK293 in plaque formation and attainment of yields and consequently became another 
favored cell line. Despite the attractiveness of these features, the level of RCA contamination remained 
similar to that of HEK293. Around the same time, a cell line complementing E1 was developed from 
A549 lung carcinoma cells [6]. This cell line had incorporated a reduced Ad5 sequence (nt505-4034) 
under the regulation of a non-Ad promoter, phosphoglycerate kinase (PGK). However the production 
of virus in this cell line was poor, although it is unclear whether this is due to a 1bp deletion in the E1B 
region, abolishing expression of the E1B-55kDa protein or another reason. Despite this, the overall 
strategy of using smaller Ad5 E1 sequences led to the development of the PER.C6 cell line [7]. 
Like the 911 cell line, PER.C6 is also based on HER cells. The Ad5 sequence incorporated into the 
cell genome was the E1A- and E1B encoding sequences, nt 459-3510, under control of the human 
PGK promoter to compensate for the removal of the 5’ endogenous E1A promoter. Furthermore, the 
coding region for the minor capsid pIX protein which is in the 3’ region following the E1B 55-kDA 
coding region was also deleted in this construct. The smaller fragment of Ad5 sequence thus 
incorporated into the cell line has limited homology to many E1-deficient adenoviral vectors and 
double homologous recombination is not possible when using an appropriately designed Ad vector, Viruses 2010, 2                  
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thereby eliminating RCA. However, further studies indicated that rare unconventional recombination 
can still occur if the Ad vector genome is not perfectly matched. There only needs to be a short stretch 
of homology between cellular DNA and the vector genome to allow recombination [15] (Figure 3) 
resulting in atypical or pseudo RCA. It was determined that while the particle does contain intact E1 
sequences, the virus cannot replicate on its own as genomic deletions also occur elsewhere in the 
vector and have been termed helper-dependent E1-positive (HDEP) viral particles [15,21]. These 
factors indicate that the design of the Ad vector still requires consideration and removal of any 
overlapping fragments to preclude these events from occurring even when using PER.C6 cells. 
However, PER.C6 is probably the best designed and most favorable cell line for the development of 
first generation Ad5 vectors for clinical development to date. PER.C6 master cell banks for cGMP 
vector production have been established and assessed (reviewed [22]). A major disadvantage to this 
cell line is that unlike HEK293 which is more freely available to the scientific community, PER.C6 
currently has strict licensing costs/uses preventing many laboratories from working with this cell line. 
Furthermore, the PER.C6 line is considered less robust than HEK293 cell line as it is less adaptable to 
serum free culture for large scale production Ad vectors. 
Figure 3. Effect of vector design on RCA free production in PER.C6 cell line. In Vector 
#1 there is a short stretch of homology with the PER.C6 Ad5 sequence that allows 
homologous recombination. This results in atypical RCA. When the vector has no 
homology (Vector #2) no homologous recombination occurs and the viral production is 
RCA free.  
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Due to the RCA issue and potential licensing issue several other laboratories have developed E1 
complementary cells that contain smaller adenoviral E1 DNA segments than HEK293 cells and can 
propagate vectors to high titers similar to those seen on HEK293 [8-11] (Table 1). All of these cell 
lines have reduced or eliminated sequence homology between cellular DNA and viral genome to 
prevent the opportunity of the double homologous recombination crossover occurring. These cell lines 
are based on human primary amniocytes, human embryonic lung HEL 299 cells or HeLa with the 
incorporated E1A region driven by an alternate promoter (as detailed in Table 1). Unfortunately, the 
HeLa cell line is not allowed for commercial use because of its high tumorigenicity.  
The requirement of the pIX sequence in first generation Ad vector producer cells has been 
questioned [6,8]. Of the more recent cell lines that contain contiguous E1A/E1B sequence, only 
PER.C6 and UR lack pIX sequences. The presence of partial pIX sequences in other cell lines could 
potentially influence RCA, however all have been reported to have significant reduction of RCA   
[8-10] as a non-homologous recombination is required at the 5’ end With respect to future cell lines 
being developed pIX sequence probably should be excluded. pIX has been described to have many 
different roles (reviewed [23,24]), including genome packaging [25,26] leading to infectious/non-
infectious particles [26] and as a transcriptional activator [27,28]. It is thought that pIX is dispensable 
for viral replication [27,28] although this may only be the case in HEK293 rather than cell lines 
lacking pIX sequences such as PER.C6 [24,29]. The major issue though with pIX is that it is a minor 
capsid protein, and while  the absence of pIX does not affect capsid assembly thermostability is 
significantly reduced due to lack of capsid incorporation [30]. Most importantly then pIX is required 
for stabilizing the capsid and providing temperature resistance that is needed for commercial 
manufacture. Therefore it is essential that pIX be expressed at a high enough level for capsid 
incorporation to achieve a commercially viable vector. In the case of first generation Ads this is 
preferable from the vector, although vectors further deleted in the pIX region could be trans-
complemented by pIX expressing cell lines to increase expression to a level that allows pIX to be 
capsid incorporated [31,32]. 
Apart from the HEK293 cell line which was generated with sheared Ad5 DNA, the main strategy 
for generating producer cell lines for E1 trans-complementation has involved insertion of the 
contiguous sequence of E1A and E1B into the cell line genome utilizing DNA plasmid based systems. 
However, new and novel approaches are being taken to reduce and eliminate RCA, while maintaining 
trans-complementation. One approach utilized adenoviral E1A and E1B gene integration into the A549 
genome at separate locations [13]. This was achieved using co-infection of cells with two retroviral 
vectors, one for each gene. Two of the stable clones attained, Ac51 and Ac139 were shown to be E1 
complementary and support production of E1-defective adenoviruses without RCA generation. 
Furthermore the titer levels attained matched those seen in HEK293 and PER.C6 cells. In a similar 
strategy a producer cell line, SL0003, was generated through sequential incorporation of E1A and E1B 
genes into A549 cells [14]. Rather than use retroviral vectors for delivery, this strategy utilized DNA 
plasmids. As with Ac51 and Ac139, SL0003 could support high titer level production without the 
generation of RCA.  
A unique approach is being explored in our own laboratory as an alternate means to overcome 
RCA. In this instance, the Ad5 sequence in HEK293 cells would be modified to contain a large ~8 kb 
spacer sequence of DNA, inserted at nt3510 (Figure 4). To achieve this modification, the spacer Viruses 2010, 2                  
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plasmid is designed to contain homologous Ad5 E1 sequences around the spacer sequence to allow for 
homologous recombination into the HEK293 genome. The insertion of spacer DNA following nt 3510 
would still allow trans-complementation of the E1A/E1B functions in E1 deleted Ad vectors, but 
should homologous recombination between the Ad5 vector and the modified HEK293 genome occur, 
the Ad5 vector genome would become too large to be packaged (Figure 4). Ad5 vector genomes up to 
105% than the normal genome size can still be packaged successfully [33], whereas in this case the 
genome size would ~114% larger than normal. One concern though is that the Ad genome could 
undergo rearrangements resulting in smaller replication competent genomes which could be packaged 
[33] and this would have to be carefully assessed once the cell line is established. We are currently 
generating the new cell line with a spacer that also contains functional cassettes expressing 
advantageous genes which would potentially allow the new cell line to have a dual purpose of high 
levels of Ad vector and protein production [12].  
Figure 4. RCA free vector production in 293-VLI Cells. An ~8 kb sequence of DNA 
containing advantageous genes, the spacer, will be incorporated into the HEK293 Ad 
sequence at nt3510. While this does not prevent homologous recombination due to 
retention of homology between the genome and Ad vector, packaging of the Ad vector will 
be suppressed due to the increased size. 
 
 
First generation Ad vectors are the workhorse vector for many vaccine and gene therapy strategies, 
although they do have limitations as discussed in the following sections. The E1 complementing 
packaging cell lines developed to produce these vectors form the basis for all cell lines utilized with 
other types of genome deleted Ad vectors. The most important aspect to arise from this work is 
overcoming RCA, and this relies not only on how much of the Ad5 E1 sequences are incorporated into 
the cell line genome, but also careful design of the vector genomes themselves. Therefore the future Viruses 2010, 2                  
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for new cell line development is the incorporation of advantageous genes into the genome to improve 
productivity, adaptability and robustness as described for the 293-VLI model.  
2. Producer cells for non-replicating second generation Ad vectors 
Second generation Ad vectors contain further genome deletions, in the E2 and/or E4 regions (see 
Figure 1). The E2 region encodes three essential proteins controlling viral replication, the DNA-
binding protein (DBP) transcribed from the E2A region, and terminal protein and viral DNA 
polymerase from E2B (reviewed [34]). E4 products are essential for productive virus infection but of 
the several possible open reading frame (ORF) products (reviewed [35]) encoded from this region it 
has been determined that only one, either ORF3 or ORF6 is absolutely required for successful viral 
growth in tissue culture [36-39]. Removal of either of E2 of E4 will inactivate de novo synthesis of 
viral proteins involved for viral DNA replication. Even though E1 proteins are removed from first 
generation vectors, delivery of high titers of E1 deleted vectors, and the presence of E1-like factors in 
many cells can allow for expression of other viral proteins [40-42]. These viral proteins would 
normally initiate a strong immune response dampening the efficacy of a first generation Ad vector  
[43-45]. Apart from lowering the immune response and thus enhancing vector safety, an additional 
benefit of removal of these genes is that larger expression cassettes can be incorporated into the 
genome, increasing the size from ~6 kb to ~9 kb.  
In the early-80s and early-90s it was demonstrated that E2 defective Ad vectors [46,47] and E4 
defective Ad vectors [48] could be propagated in trans-complementing cell lines based on HeLa and 
Vero cells respectively. Since then a wide array of cell lines, based on HEK293, 911 and E1 modified 
A549 cells, have been generated to allow propagation of Ad vectors lacking genes from the E2 and/or 
E4 regions in addition to the standard E1 deletion (Table 2) [31,49-61]. One of the main differences 
from E1 complementing cell lines, where E1A and E1B are expressed constitutively, is that several of 
these cell lines rely on the use of conditionally active transcription units or gene products to control the 
expression of these proteins as the viral products from E2A and E4 regions are toxic to the cells. For 
example, it was shown that expression of high levels of E2A viral product in the presence of E1 
proteins is toxic to cells [46]. 
E2 complementing cell lines either express E2A (DBP) or E2B (Ad DNA polymerase and/or 
precursor terminal protein) viral products. DBP is required to be expressed at high levels for successful 
viral replication and therefore most E2A complementing cell lines are prepared with controlling 
elements. The 293-C2 line [56] was constructed with constitutive gene expression, but this group 
eventually developed an alternate cell line, E2T, relying on tetracycline controlling elements [61]. The 
tetracycline system relies on two cassettes stably inserted into the genome, the transactivator protein 
(tTA) cassette and the tet operator sequences in the CMV promoter region of the E2A cassette. In the 
presence of tetracycline, E2A is not expressed, but in the absence E2A is expressed. Viral production 
in 293-C2 is about 10- to 30- fold below those of E2 wild type vectors [56], while E2T in the absence 
of tetracycline produced viral yields of E2A deleted Ad vectors similar to that of wild E2 vectors [61]. 
Other E2A cell lines, 293-E2A [59] and AE1-2a [53] rely on glucocorticoid-responsive elements such 
as the mammary tumor virus promoter (MMTV) long terminal repeat and mouse mammary tumor 
virus promoter (pMAM) respectively, with expression induced by dexamethasone. Growth kinetics of Viruses 2010, 2                  
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an E1/E2A Ad vector in 293-E2A was similar to that of a comparative first generation Ad vector, but 
infectious particles were reduced by 5- to 30- fold under this system [59]. In the AE1-2a cell line, a 
delay in cytopathic effect was seen with an E1/E2A/E3 deleted Ad vector yet infectious particles 
yields were comparable levels to a first generation Ad vector in this instance [53]. 
Table 2. E1/E2 and E1/E4 complementary producer cell lines. 
Cell Line  Parental 
Cells 
E2 or E4 
Complementatio
n 
Viral 
Products 
Inducible 
System 
Refs 
VL2-20 and 
VK10-9
a 
HEK293 E4  All  ORFs  Glucocorticoid  [31] 
293-E4  HEK293  E4  All ORFs  cAMP   [49] 
C7  LP-293  E2B   Pol and pTP
b No  [50,57]   
293-ORF6  HEK293 E4  ORF6  Metal
c [51] 
MT-ORF6  HEK293 E4  ORF6  Metal  [52] 
[52]  MMTV-ORF6  HEK293 E4  ORF6  Glucocorticoid 
AE1-2a  A549
d E2A  DBP  Glucocorticoid  [53] 
293-pTP  HEK293 E2B  pTP  Tetracycline  [54] 
IGRP2  HEK293  E4   ORF6 and 7  Glucocorticoid  [55] 
293-C2  HEK293 E2A    DBP  No  [56] 
911E4  911 E4  All  ORFs  Tetracycline  [58] 
293-E2A  HEK293 E2A  DBP  Glucocorticoid  [59] 
[59] 
[59] 
293-E4  HEK293 E4  All  ORFs  Yes
e 
293-E4ORF6+7  HEK293  E4  ORF6 and 7  Tetracycline 
A70.S54  AE1-2a E2A/E4  DBP/All  ORF  Glucocorticoid  [60] 
E2T  HEK293 E2A  DBP  Tetracycline  [61] 
a  These lines also express pIX under the control of metal inducible metallotheinen promoter.  
b  C7 cell line was first generated to express only Ad DNA polymerase [50] and then modified to express 
  precursor terminal protein [57]. 
c  Zinc-inducible. 
d  The AE1-2A cell line is based on A549 that also encodes E1 region (552 to 4090) under control of a 
  minimal glucocorticoid-response element (GRE5) promoter. 
e  The E4 cassette was under control of the E1A inducible homologous E4 promoter. 
 
It is known that E2B mRNA is expressed at low levels in Ad-infected cells [62] and therefore it is 
thought that cell lines expressing low levels of these viral products will be more appropriate in Viruses 2010, 2                  
 
 
1690
complementing deletions in Ad vectors. With this in mind two main cell lines have been generated. 
The C7 cell line was sequentially generated to express Ad2 140kDa DNA polymerase protein [50] and 
the precursor terminal protein (pTP) [57]. Both genes are constitutively expressed under the Rous 
sarcoma virus-long terminal repeat promoter element and cell growth and viability was not affected. 
Viruses containing mutations in the E2B region were successfully complemented by the C7 cell line to 
permit viral propagation at levels similar to E2B wild type vectors. 293-pTP, complementing only for 
the pTP uses a tetracycline regulatory system, wherein the cell line contains the tetracycline 
repressor/VP16 transactivator protein (tTA) and the pTP is under control of a tetracycline-dependent 
promoter [54]. This system was found to improve cell growth and viability over a previous version of 
293-pTP which constitutively expressed pTP [63]. These tetracycline controlled 293-pTP cells were 
shown to efficiently complement a temperature sensitive pTP Ad vector when the cells expressed high, 
inducible levels of pTP.  
Initial studies with E1/E4 deleted vectors utilized the incorporation of full length E4 into cell lines 
[31,49]. VL2-20 and VK10-9 cells, containing full length E4 controlled by dexamethasone inducible 
MMTV promoter, were permissible to propagation of an E4 deleted vector, but a delay in CPE was 
seen and 10-fold lower yields obtained [31]. However another full length E4 expressing cell line was 
reported, with the E4 cassette under the control of a mouse alpha inhibin promoter containing a cAMP 
response element that demonstrated yields of E1/E4-deleted vectors attained were comparable to E1-
deleted vectors [49]. In 1996, two groups developed E4-ORF6 cell lines confirming that only one E4 
open reading frame is required to complement for the E4 region. These cell lines, 293-ORF6 [51] and 
MT-ORF6 [52], were based on HEK293 cells with ORF6 under the control of a zinc inducible sheep 
metallotheinen promoter. In MMTV-ORF6 [52] the E4 ORF6 was under the control of the MMTV 
promoter as the inducible elements. An E1/E4 deleted Ad vector was reported to propagate with the 
MT-ORF6 and MMTV-ORF6 lines [52] but yields were not compared with an E1 deleted vector. In 
293-ORF6 cells, yields of E1/E4 deleted Ad vector were equivalent to E1 deleted vector levels [51]. 
Even though these E4-ORF4 expressing cell lines were reported to successfully complement the 
deletion of E4, several other full length E4 and E4-ORF6+7 expressing cell lines were generated from 
1996 onwards [55,58-60]. IGRP2 [55], with ORF6+7 under the control of the MMTV long terminal 
repeat, 911E4 [58] under a tetracycline system, and 293-E4 [59] under E1A homologous inducible E4 
promoter and 294-E4ORF6+7 [59] under a tetracycline system all showed similar results in that yield 
of E1/E4 deleted vectors were reduced. However, A70.S54, a cell line complementing for triple 
deleted vector (E1/E2A/E4) was able to produce this vector as comparable levels to wild-type E4 
vectors [60]. Some of the differences seen in the yields and viral growth are due not only to the cell 
line utilized but also to the differences in the vector design. For example, a small insert placed in the 
deleted E4 region can increase production levels by as much as 30 fold [51]. 
Despite extensive development of second-generation Ad vectors and cell lines throughout 1995 to 
2000 many of these vectors have faded into the background. Yields of these vectors can be reduced 
when compared to respective first generation vectors, depending on the cell line and vector system 
used. Furthermore comparative studies between E2A or E4 and their respective isogenic E1 deleted 
vectors indicate that E2A deletions confer limited improvement [59,64,65] while the results are more 
controversial with respect to E4 deletions [52,59,66,67]. Although attenuated toxicity towards the 
vectors can be seen, stable transgene expression is generally not seen. These vectors have therefore Viruses 2010, 2                  
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been superceded by high capacity Ad vectors (HC-Ad) for long-term transgene expression (reviewed 
[68]). However, several of the producer cell lines have been utilized for other purposes as seen in the 
next two sections, but only the second generation producer line, 293-ORF6 [51] has been used in GMP 
productions. 
3. Producer cells for high capacity Ad vectors 
HC-Ad vectors, the so-called “gutted” Ads form the third class of non-replicative Ad vectors (see 
Figure 1). With these vectors, all the viral genes are deleted leaving only the cis-acting sequences 
necessary for viral DNA replication and packaging, allowing for large therapeutic gene incorporation 
or multiple genes. Furthermore, apart from pre-existing immunity, additional immune response to de 
novo viral protein production is essentially removed. These vectors when used in vivo result in long-
term, high-level transgene expression combined with negligible toxicity (review [68]). The main 
disadvantage for these vectors is the complex production due to the need not only for a suitable 
producer cell line, but also a complementing Ad vector, so-called helper Ad vector (HAd), which 
provides the necessary packaging proteins of the viral particle. Thus far the process has not been 
simplified to just the HC-Ad and a producer cell line that can trans-complement for the entire Ad 
genome, as there is likely toxicity associated with expression of all the viral proteins within the cell 
[60]. The requirement of the HAd brings about the problem of contamination from the HAd when 
using E1 complementing producer cells. Several methodologies have been developed to construct HC-
Ads (review [68]) but the predominant system involves Cre recombinase or a similar recombinase. 
To reduce contamination of HAd a helper-dependent system was developed that involved 
generating a cell line expressing Cre recombinase, 293Cre4, in combination with modifying the HAd 
to contain loxP sites flanking the packaging site [69]. Due to the expression of Cre recombinase in the 
producer cell line the packaging signal is excised thus preventing packaging of the helper virus DNA. 
Several comparable Cre- [70-75] and/or FLP- [76,77] based systems have been designed based on the 
293Cre4 Cre/Lox system. There are fundamental differences between the HAd, HC-Ad, cell lines and 
protocols between laboratories, however vector design and general protocol discussion is outside of 
the realm of this particular review. With respect to the producer cell lines, Cre or FLPe recombinase 
expressing lines were derived from E1 producer cell lines such as HEK293 [70,77-79] and PER.C6 
[75], or 293 producer cells complementing E2A, E2T [72] and C7 [73] (Table 3). Generally the 
introduction of the Cre or FLPe recombinase cassette was through transfection of the appropriate 
plasmid. In the case of the development of PER.C6-Cre, this was conducted using a retroviral vector. 
It should be noted that even with this type of system, contamination is not fully eliminated (0.1% to 
1% is usually seen), but physical separation of the HC-Ad and HAd through CsCl ultracentrifugation 
can address this issue. For small preparations this is generally acceptable, however for industrial-scale 
clinical grade vector production further measures have to be taken [78], especially as some of this 
contamination can contain packaging competent HAd. Palmer & Ng, 2003 [78] have described further 
modifications to the HAd as means to improve the contamination issue by reversing the packaging 
signal with respect to the HC-Ad thus rendering the recombinant genomes too large to be packaged if 
homologous recombination occurs [80]. RCA is still potentially an issue with these vectors and 
therefore PER.C6 cells expressing Cre is a useful cell line to prevent this [75]. Another issue with the Viruses 2010, 2                  
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production of HC-Ad is that low titer levels are usually attained due to using adherent cell cultures. 
The 116 Cre expressing cell line was derived from a subclone of HEK293 cells, 293N3S [81] which 
can be cultured in suspension and this greatly enhances the titer levels [78], as has been seen with 
suspension cultures of PER.C6-Cre [75]. Even though these vectors are complex to produce, their 
increased cassette incorporation, improved expression and lower immunity issues drive their 
development. 
Table 3. High capacity Ad vector producer cell lines using recombinase system. 
Cell Line  Parental Cells  Ad vector 
complementation 
Recombinase 
System 
Refs 
293Cre4  HEK293 E1  Cre  recombinase  [69] 
293cre415
a  293Cre4 E1  Cre  recombinase  [79] 
CRE8  HEK293 E1  Cre  recombinase  [70] 
CreE  E2T E1/E2A  Cre  recombinase  [72] 
293FLP   HEK293 E1  FLPe  recombinase  [76] 
[76]  293CreFLP  293Cre4 E1  either
b 
293-FLPe6  HEK293 E1  FLPe  recombinase  [77] 
C7-Cre  C7 E1/E2B  Cre  recombinase  [73] 
116  293N3S
c E1  Cre  recombinase  [78] 
PER.C6-Cre  PER.C6 E1  Cre  recombinase  [75] 
a  Chen et al., 1996 [79] developed the cell line as described in the table, but Sandig et al., 2000 [71] 
  utilized the cell line in a Cre/lox helper dependent Ad system. All other cell lines documented in the 
  table have been developed by the groups referenced in the table. 
b  This cell line can be used with Cre or FLPe recombinase. 
c  This is a subclone of HEK293 that can be cultured as an adherent cell line or in suspension [81]. 
 
4. Producer cell lines for novel Ad vector serotypes 
Within the human population there are high titers of pre-existing neutralizing antibodies against 
Ad5 and Ad2 serotypes [82-85] due to the general exposure to Ads. Therefore while most research and 
development of Ad vectors has utilized the Ad5 and Ad2 serotypes, efficacy of these vectors can be 
severely compromised [86-89]. An additional observation is that upon re-administration liver toxicity 
is increased [90], and in human blood neutralizing antibodies may activate complement and induce 
inflammatory reactions [91]. In an attempt to circumvent this issue Ad vectors derived from different 
human [83,84,92-104] and animal [105-110] serotypes, to which the human population has a lower 
prevalence of neutralizing antibodies, are currently being investigated. Non-replicating versions of 
alternate serotypes face similar issues to the first-, second generation and HC-Ads based on Ad5 Viruses 2010, 2                  
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serotype, regarding which producer cell line is suitable to achieve production and propagation of the 
vector. 
Human subgroup B adenoviruses, in particular, Ad11 and Ad35 are emerging as strong contenders 
for replicating defective vectors [83,84,93,95,96,98,100]. E1-deleted Ad35 and Ad11 vectors cannot 
be propagated on regular E1 producer cell lines, although E1A-only deleted Ad35 can be propagated 
on PER.C6 [83]. Therefore two initial approaches were taken to propagate E1-deleted vectors. One 
utilized existing second generation producer cell lines following the observation that Ad7 vectors 
(another subgroup B adenovirus) could be propagated in the E4 complementing cell line, 293-ORF6 
[92,94]. VK10-9 which complements E1/E4 deletions [31] produced yields of Ad35 that were slightly 
lower yields than that seen with Ad5 [95], and A70.S54 [60], a triple deletion complementing cell line 
(E1/E2A/E4), was also used [83] albeit producing lower yields than an E1A deleted vector.  
In the second approach new packaging cell lines CRE35G3 [93] and PER.C6/55K [84] that express 
Ad5 E1 and Ad35 E1B-55kDa proteins have been derived. These cell lines allow successful 
propagation of E1-defective Ad35 vectors to similar viral titers as Ad5. An Ad11 packaging cell line 
was also developed, 293-Ad11-E1B55K, which was produced by transfecting and generating a stable 
clone from 293 cells with a plasmid containing the Ad11 E1B55K gene under the control of human 
PGK [98]. This E1B55K packaging line approach has also been utilized for the construction of another 
subgroup B serotype, E1-deleted Ad3 in which 911 cells were modified to express Ad3 E1B55K gene 
[97]. While production yields of these defective viruses match those of Ad5, it has been noted that 
Ad35 and Ad11 vectors have increased viral particle to infectious particles compared with Ad5 when 
propagated on the respective E1B55K lines. This effect is attributed to cellular receptor properties as 
subgroup B viruses such as Ad3, Ad11 and Ad35 use CD46 receptor for infection rather than CAR that 
all other Ad serotypes use [111-113]. One important advantage demonstrated from the studies with 
Ad35 and Ad11, is that replication-competent Ad35 or Ad11 is absent in the viral preparations due to 
lack of homology between the genomic DNA of the virus and the E1B55K packaging cell lines. 
Recently a new strategy for Ad35 has been developed relying on further modification of the Ad 
vector genome [100]. It has been reported that the Ad5 E1B55kDa protein forms a complex with E4 
ORF6 proteins to increase selective export of late viral mRNA [114-116]. The observation that E1-
deleted Ad35 vectors only propagate in cells lines expressing either E4-ORF6, or Ad35 E1B55K 
indicate for successful viral replication to occur these proteins should derive from the same subgroup. 
Therefore, E1-deleted Ad35 vectors have further been modified to have the E4 region replaced with 
Ad5 E4-ORF6 and this permits viral propagation on unmodified PER.C6 cells [100] whereas 
previously only E1A-deleted vectors could be propagated on this cell line. The main benefit of 
modifying the vectors this way allows for propagation on well established and regulatory approved 
cell lines resulting in one less step when moving the novel Ad vector itself through regulatory 
approval. This E4 serotype switching methodology has also been applied to the development of a 
subgroup D serotype Ad49 vector [101,103] as well as to recombinant Ad vaccine vectors derived 
from several subgroup B (Ad11, Ad50) and subgroup D viruses (Ad26, Ad48) [103]. Other human 
serotypes that have been utilized however can be propagated in E1 producer cells and E1/E4 producer 
cells. This includes a different subgroup D serotype, Ad19a that was E1/E3- deleted and propagated to 
wt levels in HEK293 cells [102], a subgroup C serotype Ad6 based vaccine that can be propagated on Viruses 2010, 2                  
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PER.C6 cells [99] and a subgroup F serotype, Ad41 which when E1 deleted can still be propagated on 
293-ORF6 cells [104]. 
Several non-human serotypes derived from bovine [106], canine [105,107] and simian   
[108-110,117] sources have been developed as potential E1-deleted Ad vectors for use as gene 
delivery or vaccine vectors for human therapies. In the case of the bovine, BAV-3 and canine, CAV-2 
vectors, specialized E1 producer cells based on appropriate species cell lines, such as bovine kidney 
and fetal retinal cells expressing Ad5 E1 sequences [106] and canine kidney cells expressing the  
CAV-2 E1 [105], have been developed to package and propagate these vectors. The chimpanzee 
derived Ad vectors of subgroup E can be propagated on HEK293 cells and therefore can be grown 
under standard methods [108,109]. However, as with Ad11, Ad35 and other human subgroup B 
vectors, chimpanzee derived Ad vectors of subgroup B cannot be propagated on regular E1 producer 
cell lines. In this instance, rather than develop new producer cell lines, a chimeric vector approach is 
utilized. This strategy involves the central portion of the genome, which harbors several of the 
structural proteins to be derived from the subgroup B virus, but the flanking regions are from a non-
subgroup B virus allowing these chimeric vectors to be propagated on HEK293 cells [110,117]. 
Furthermore, this strategy is similar to that of modifying the E4 region of human subgroup B viruses, 
to allow propagation in well characterized cell lines. 
One of the interesting observations to arise from the use of producer cell lines for alternate Ad 
serotypes is that in many cases there was a shift from developing new producer lines towards further 
vector genome modifications. While it seemed necessary to generate specialized producer lines for the 
human subgroup B viruses, once their structure and biology was further delineated, it was realized that 
it is simpler to incorporate further vector modifications in the E4 region that allow for their 
propagation on a well-characterized E1 complementing cell line. This paradigm was also utilized with 
respect to simian based Ad vectors and is worth considering if there is rapid need to move a novel Ad 
vector from bench to bedside. 
5. Conclusions 
Throughout the last 3 decades a wide array of producer cell lines have been developed for the 
production of Ad vectors. There are still only a few cell lines approved for cGMP production of 
replication-defective Ad5 vectors, as the regulatory requirements include a very extensive process of 
cell banking and testing. As far as we know at the present time only HEK293, PER.C6, N52.E6,  
293-ORF6 and 293FLP cell lines have approval for cGMP production of non-replicating Ad vectors, 
although unmodified A549 cells have been approved for cGMP production of replicating Ad vectors. 
While other laboratories develop additional cell lines, either as research tools to generate novel Ad 
vectors, to overcome RCA or licensing issues, regulatory considerations for cell lines should always 
factor into the terms of moving Ad vectors from bench to bedside in a time appropriate manner. 
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